Azitra denies report of $44 million securities offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Azitra, Inc. Addresses False Report Regarding Sale of Securities
November 7, 2025 6:00 AM ESTBRANFORD, Conn., Nov. 7, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it has come to the Company's attention that a report has been circulated claiming that the Company priced a $44 million registered direct offering. This report is false and should not be relied upon.
... More


